Background Two-thirds of the 350 million people infected with chronic hepatitis B virus live in the Asia-Pacific region. Aim To compare the effects of adefovir dipivoxil therapy between Asian and Caucasian patients with chronic hepatitis B. Methods The safety and efficacy of 10 mg of adefovir dipivoxil was compared to placebo in 501 Asian (n = 259) or Caucasian (n = 242) HBeAg+ and HBeAg) chronic hepatitis B virus patients treated for 48 weeks in two randomized, double-blind, placebo-controlled studies.
|Pages (from-to)||1419 - 1428|
|Number of pages||10|
|Journal||Alimentary Pharmacology & Therapeutics|
|Publication status||Published - 2007|